Amneal Pharmaceuticals – By Most Measures, A Fundamentally Undervalued Company (NYSE:AMRX)

Office notebook with text written note I FEEL UNAPPRECIATED - feeling undervalued at work when hard work and achievements go unnoticed or not recognized

ariya j/iStock via Getty Images

Investment Overview

I last covered Amneal Pharmaceuticals (NYSE:AMRX) for Seeking Alpha in a post published in March 2022. I gave the stock a “Buy” rating – at the time, Amneal stock traded at $4 per share, and although it had sunk as low as $1.3 per

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *